Seattle Genetics Announces FDA Regular Approval of ADCETRIS® (Brentuximab Vedotin) for Classical Hodgkin Lymphoma Patients at High Risk of Relapse or Progression as Post-Autologous Hematopoietic Stem
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
Go back to Seattle Genetics Announces FDA Regular Approval of ADCETRIS® (Brentuximab Vedotin) for Classical Hodgkin Lymphoma Patients at High Risk of Relapse or Progression as Post-Autologous Hematopoietic Stem
August 18, 2015 11:12 AM EDT
Needham & Company reiterated a Buy rating and $60.00 price target on Seattle Genetics (NASDAQ: SGEN) following the announced approval of Adcetris in Hodgkin's Lymphoma patients with high risk for relapse after stem cell transplant. Approval in this indication was based on the AETHERA... More
August 18, 2015 10:13 AM EDT
Leerink Partners reiterated an Outperform rating and $56.00 price target on Seattle Genetics (NASDAQ: SGEN) following the announced FDA approval of Adcetris. SGEN announced the approval after market close. The Adcetris will be used in the AETHERA setting for Hodgkins lymphoma patients at high... More
August 17, 2015 4:10 PM EDT
Seattle Genetics (NASDAQ: SGEN) announced that the U.S. Food and Drug Administration (FDA) has approved ADCETRIS (brentuximab vedotin) for the treatment of patients with classical Hodgkin lymphoma (HL) at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation. The approval is based on a phase 3 clinical trial called AETHERA that was designed to compare up to 16 cycles (approximately one year) of ADCETRIS therapy administered every three weeks following auto-HSCT to placebo. The primary endpoint was met with a significant improvement in median progression-free survival (PFS) of 42.9 months (95% CI: 30.4, 42.9) for... More
